Wow_老虎社区_美港股上老虎

2021-10-15

Wow

Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen 股价早盘上涨超过 10%</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":825229826,"tweetId":"825229826","gmtCreate":1634230305373,"gmtModify":1634230366411,"author":{"id":4092290440523870,"idStr":"4092290440523870","authorId":4092290440523870,"authorIdStr":"4092290440523870","name":"Bayleaze","avatar":"https://static.tigerbbs.com/4cce861b2b176dd8d8c481f6fa88fe0d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Wow</p></body></html>","htmlText":"<html><head></head><body><p>Wow</p></body></html>","text":"Wow","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/825229826","repostId":1108820000,"repostType":4,"repost":{"id":"1108820000","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1634225594,"share":"https://www.laohunote.com/m/news/1108820000?lang=zh_CN&edition=full","pubTime":"2021-10-14 23:33","market":"us","language":"en","title":"Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen 股价早盘上涨超过 10%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108820000","media":"Tiger Newspress","summary":"Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week.\n\nThe bi","content":"<p>Ocugen stock jumped more than 10% in morning trading.The share&nbsp;rose more than 40% this week.</p><p><blockquote>Ocugen 股价在早盘交易中上涨超过 10%。该股本周上涨超过40%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4d6529ae3a1b252bbc25776ab15e3e3c\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.</p><p><blockquote>今天上午，由于印度主题专家委员会批准新冠肺炎疫苗科瓦克辛用于2至18岁儿童的紧急使用，该生物技术公司的股票正在北上。这种疫苗是全球首批获得如此广泛的紧急使用授权标签的疫苗之一。</blockquote></p><p> Ocugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.</p><p><blockquote>Ocugen 与印度 Bharat Biotech 合作，在加拿大和美国将科瓦克辛商业化。两人现在正在等待世界卫生组织关于该疫苗紧急使用申请的消息。这一关键的监管决定随时都会做出。</blockquote></p><p> Ocugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.<b>Novavax</b>'s highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.</p><p><blockquote>Ocugen的目标是成为加拿大和美国等主要发达市场重要的二到三线新冠肺炎疫苗参与者。这一策略的问题是，在这些高价值地区已经有过剩的新型冠状病毒疫苗，更多的疫苗即将到来。<b>诺瓦瓦克斯</b>例如，备受期待的 COVID-19 疫苗 NVX-CoV2373 将于 2022 年初在美国上市。因此，目前还不完全清楚像 Ocugen 这样的后来者会留下多少商业机会。</blockquote></p><p> Is Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.</p><p><blockquote>Ocugen 的股票值得买入吗？可以肯定的是，这是一个极其积极的监管发展。但这不太可能对疫苗在加拿大或美国的监管命运产生任何影响。</blockquote></p><p> That said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.</p><p><blockquote>也就是说，从长远来看，这家生物技术公司的股票应该仍然表现良好。如果该疫苗能够在这些日益拥挤的市场中开辟一个有利可图的利基市场，并且该公司拥有商业许可证，那么 Ocugen 最终可能会获得健康且可能相当持久的收入来源。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen stock jumped more than 10% in morning trading<blockquote>Ocugen 股价早盘上涨超过 10%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen stock jumped more than 10% in morning trading<blockquote>Ocugen 股价早盘上涨超过 10%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-10-14 23:33</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Ocugen stock jumped more than 10% in morning trading.The share&nbsp;rose more than 40% this week.</p><p><blockquote>Ocugen 股价在早盘交易中上涨超过 10%。该股本周上涨超过40%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/4d6529ae3a1b252bbc25776ab15e3e3c\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.</p><p><blockquote>今天上午，由于印度主题专家委员会批准新冠肺炎疫苗科瓦克辛用于2至18岁儿童的紧急使用，该生物技术公司的股票正在北上。这种疫苗是全球首批获得如此广泛的紧急使用授权标签的疫苗之一。</blockquote></p><p> Ocugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.</p><p><blockquote>Ocugen 与印度 Bharat Biotech 合作，在加拿大和美国将科瓦克辛商业化。两人现在正在等待世界卫生组织关于该疫苗紧急使用申请的消息。这一关键的监管决定随时都会做出。</blockquote></p><p> Ocugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.<b>Novavax</b>'s highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.</p><p><blockquote>Ocugen的目标是成为加拿大和美国等主要发达市场重要的二到三线新冠肺炎疫苗参与者。这一策略的问题是，在这些高价值地区已经有过剩的新型冠状病毒疫苗，更多的疫苗即将到来。<b>诺瓦瓦克斯</b>例如，备受期待的 COVID-19 疫苗 NVX-CoV2373 将于 2022 年初在美国上市。因此，目前还不完全清楚像 Ocugen 这样的后来者会留下多少商业机会。</blockquote></p><p> Is Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.</p><p><blockquote>Ocugen 的股票值得买入吗？可以肯定的是，这是一个极其积极的监管发展。但这不太可能对疫苗在加拿大或美国的监管命运产生任何影响。</blockquote></p><p> That said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.</p><p><blockquote>也就是说，从长远来看，这家生物技术公司的股票应该仍然表现良好。如果该疫苗能够在这些日益拥挤的市场中开辟一个有利可图的利基市场，并且该公司拥有商业许可证，那么 Ocugen 最终可能会获得健康且可能相当持久的收入来源。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108820000","content_text":"Ocugen stock jumped more than 10% in morning trading.The share rose more than 40% this week.\n\nThe biotech's stock is moving northward this morning on the news that the COVID-19 vaccine, Covaxin, was granted emergency use approval for children ages 2 to 18 by India's Subject Expert Committee. This vaccine is among the first to receive such a broad emergency use authorization label in the entire world.\nOcugen is partnered with India's Bharat Biotech to commercialize Covaxin in Canada and the United States. The pair are now waiting on word from the World Health Organization on the vaccine's emergency use application. This critical regulatory decision is expected any day now.\nOcugen's goal is to become an important second- to third-tier COVID-19 vaccine player in key developed markets like Canada and the United States. The problem with this strategy is that there are already a surfeit of novel coronavirus vaccines in these high-value territories, with more on the way.Novavax's highly anticipated COVID-19 vaccine known as NVX-CoV2373, for example, should be available in the U.S. early in 2022. As a result, it's not entirely clear how much of a commercial opportunity will be left for late-comers like Ocugen.\nIs Ocugen's stock a buy on this news? This is an extremely positive regulatory development, to be sure. But it is unlikely to have any bearing on the vaccine's regulatory fate in either Canada or the United States.\nThat said, the biotech's shares should still perform well over the long term. If the vaccine can carve out a profitable niche in these increasingly crowded markets where the company owns a commercial license, Ocugen could end up with a healthy and perhaps fairly long-lived revenue stream.","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2768,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/825229826"}